Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Current Depressive Episode Clear all
Terminated Phase 2 Interventional Results available

Open Label Extension for GLYX13-C-202, NCT01684163

NCT02192099
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Rapastinel (225 mg/450 mg IV administration)
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jul 23, 2026, 7:04 AM EDT
Completed No phase listed Observational Results available

Treatment-Resistant Depression Registry

NCT00320372
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
55
States / cities
Tucson, Arizona • Beverly Hills, California • Garden Grove, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Jul 23, 2026, 7:04 AM EDT
Completed No phase listed Observational

Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)

NCT05708222
View directory record Official record
Conditions
Depressive Episode, Depression, Depressive Disorder, Depressive Disorder, Major, Depression Mild
Interventions
MEB-001
Device
Lead sponsor
Medibio Limited
Industry
Eligibility
22 Years to 75 Years
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Bradenton, Florida • Blaine, Minnesota • Plymouth, Minnesota + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants

NCT01684163
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
GLYX-13 5 mg/kg, GLYX-13 10 mg/kg, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Encino, California • Los Alamitos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Jul 23, 2026, 7:04 AM EDT
Recruiting Phase 2 Interventional

ALTO-100 in Bipolar Disorder With Depression (BD-D)

NCT06656416
View directory record Official record
Conditions
Bipolar Disorder I or II With a Major Depressive Episode
Interventions
ALTO-100, Placebo
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
27
States / cities
Chandler, Arizona • Phoenix, Arizona • Yuma, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Phase 2 Interventional

Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

NCT01234558
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
GLYX-13
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Phase 4 Interventional Results available

Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation

NCT01134731
View directory record Official record
Conditions
Major Depressive Disorder, Suicidal Ideation
Interventions
paliperidone, lithium, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treating Depression With Transcranial Direct Current Stimulation (tDCS)

NCT00481988
View directory record Official record
Conditions
Depression
Interventions
transcranial direct current stimulation, iomed phoresor transcranial direct current stimulation
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Single Session of tACS in a Depressive Episode

NCT03449979
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Premenstrual Dysphoric Disorder, Depressive Episode
Interventions
XCSITE100 Stimulator Sham, XCSITE100 Stimulator tACS
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Not applicable Interventional Results available

Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder

NCT03288714
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Depressive Episode, Major Depressive Disorder
Interventions
Synchronized Transcranial Magnetic Stimulation (sTMS), Sham Stimulation
Device
Lead sponsor
Wave Neuroscience
Industry
Eligibility
22 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Phase 3 Interventional Results available

A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

NCT03573297
View directory record Official record
Conditions
Bipolar I Disorder, Mania, Depression
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
46
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Not applicable Interventional Results available

Genomics Used to Improve DEpression Decisions

NCT02109939
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
GeneSight Psychotropic
Genetic
Lead sponsor
Assurex Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
61
States / cities
Birmingham, Alabama • Bellflower, California • Chino, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

NCT03692910
View directory record Official record
Conditions
Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
11
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 23, 2026, 7:04 AM EDT
Active, not recruiting Not applicable Interventional

Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder

NCT05849402
View directory record Official record
Conditions
Bipolar II Disorder, Most Recent Episode Major Depressive, Current Depressive Episode, Treatment Resistant Depression
Interventions
Active Comparator: Active aiTBS, Sham Comparator: Sham aiTBS
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 7:04 AM EDT